ADDvise Group’s subsidiary Germa has received an order from Saab AB (publ). The order has a total value of approximately SEK 32.5 million. The order relates to the delivery of equipment and related components. The deliveries will be separated and are expected to be made during 2025 as agreed between Germa and Saab. Payment will … Read more
The departing CEO Rikard Akhtarzand has agreed with Kenneth Lindqvist, one of the major shareholders of ADDvise, to divest 2,500,000 shares of series A to Kenneth Lindqvist, privately and through companies. The total purchase price for the shares amounts to SEK 37,500,000. The divestment of the shares is subject to approval by the Swedish Inspectorate … Read more
The second quarter saw continued robust revenue growth and improved profit. Organic growth remains burdened by challenging comparables from 2023 driven by very strong sales in pharmaceuticals and rental of equipment for clinical trials, but with organic order intake well back in positive territory with several large new orders, we are optimistic about the second … Read more
The board of directors of ADDvise Group announces today that the chairman of the board, Staffan Torstensson, is appointed CEO of the company, effective September 1, 2024. In light of this transition, the board will convene an extraordinary general meeting in the near future to elect Per Åhlgren as board member and new chairman of … Read more
Axelerist, an ADDvise Group company, has received an order from Vertex Pharmaceuticals, a global biotechnology company, for the sale and rental of medical and laboratory equipment. The order value amounts to USD 1.4 million. Delivery will take place over a four-year period starting in Q3 2024. For further information, please contact: Rikard Akhtarzand, CEO … Read more
ADDvise Group AB (publ) (“ADDvise Group”) has initiated the process of listing the company’s A and B shares on Nasdaq Stockholm. The change of listing venue is expected to be completed in the first quarter of 2025. As part of the continued development of ADDvise Group, the company has for some time reviewed the possibility … Read more
ADDvise Group has appointed Oliver Humlen as new CEO, effective September 1, 2024. He will succeed Rikard Akhtarzand who will take up the position as CEO of Your.Online, a European serial acquirer platform backed by Strikwerda Investments. Rikard will remain a significant and long-term shareholder in ADDvise Group and is nominated to the Board … Read more
MRC Systems, an ADDvise Group company, has received an order from leading Omani biopharmaceutical company Opal Bio Pharma. The initial order value amounts to USD 11.3 million with an extension option amounting to an additional USD 6.8 million. The order involves the design, supply, installation and validation of cleanroom panelling, HVAC and accessories for … Read more
The first quarter saw a continued favourable revenue development. The Lab segment delivered strong organic growth whereas our pharmaceuticals business affected the Group negatively. The changing product mix resulted in lower margins. Work continued to optimise the capital structure and profit for the period improved. January – March 2024 Net revenue for the period was … Read more
ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from the Kanta-Häme region worth EUR 1.25 million. The allocation decision pertains to the delivery of x-ray equipment to three hospitals in the region during 2024 and early 2025. The allocation decision is subject to a customary appeals period. For further … Read more